Specificity, Inc. (SPTY)
OTCMKTS · Delayed Price · Currency is USD
0.4499
0.00 (0.00%)
At close: Aug 1, 2025
Specificity Employees
Specificity had 8 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
8
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$111,292
Profits / Employee
-$89,875
Market Cap
6.12M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8 | 0 | - |
| Dec 31, 2023 | 8 | -12 | -60.00% |
| Dec 31, 2022 | 20 | -24 | -54.55% |
| Dec 31, 2021 | 44 | 37 | 528.57% |
| Dec 31, 2020 | 7 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| GlobalTech | 291 |
| Scientific Energy | 883 |
| LICT Corporation | 368 |
| Hartford Creative Group | 19 |
| Alpha One | 25 |
| Yinfu Gold | 3 |
| Karbon-X | 7 |
Specificity News
- 3 days ago - Specificity Expands to Europe, Bringing Precision Targeting and Human-Only Ad Tech to a Market Ripe for Disruption - Accesswire
- 9 days ago - Oral Cancer Rapid Test Kits Business Report 2025 | Market to Reach $1.2 Billion by 2030 - Advancements in Biomarker Identification Propel Development of High-Specificity Rapid Test Kits - GlobeNewsWire
- 11 days ago - Specificity Regains Status as a Fully Reporting U.S. Securities and Exchange Commission Current Filer - Accesswire
- 15 days ago - Tumor Ablation Market Research Report 2025-2032 | Radiofrequency Ablation Leads, Offering Efficiency and Specificity Across Key Organ Treatments - GlobeNewsWire
- 2 months ago - Specificity Cracks the Code on Cross-Channel Precision: Video Ads Served to the Same High-Intent, Bot-Free Audiences Engaged on Display and Social - Accesswire
- 2 months ago - Specificity Guarantees High-Quality B2B Leads - Disrupting the Broken Lead Gen Model - Accesswire
- 2 months ago - Specificity Builds Dominant CTV Campaign Capabilities, Reinforces Position as Industry's Leading Hybrid Marketing Agency - Accesswire
- 3 months ago - Clasp Therapeutics Doses First Patient in Phase 1 Clinical Trial With a First-in-Class T-Cell Engager Designed to Target Cancer Cells With Absolute Specificity - Business Wire